A detailed history of Everhart Financial Group, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Everhart Financial Group, Inc. holds 10,696 shares of ABBV stock, worth $1.8 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
10,696
Previous 6,637 61.16%
Holding current value
$1.8 Million
Previous $1.03 Million 89.4%
% of portfolio
0.57%
Previous 0.37%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $648,709 - $739,143
4,059 Added 61.16%
10,696 $1.95 Million
Q4 2023

Jan 12, 2024

SELL
$137.6 - $154.97 $79,670 - $89,727
-579 Reduced 8.02%
6,637 $1.03 Million
Q3 2023

Oct 25, 2023

BUY
$133.59 - $154.65 $142,139 - $164,547
1,064 Added 17.3%
7,216 $1.08 Million
Q2 2023

Jul 13, 2023

SELL
$132.51 - $164.9 $110,778 - $137,856
-836 Reduced 11.96%
6,152 $828,000
Q1 2023

Apr 25, 2023

BUY
$144.61 - $166.54 $63,917 - $73,610
442 Added 6.75%
6,988 $1.11 Million
Q4 2022

Feb 09, 2023

BUY
$138.31 - $165.87 $73,995 - $88,740
535 Added 8.9%
6,546 $1.06 Million
Q3 2022

Oct 12, 2022

BUY
$134.21 - $153.93 $58,783 - $67,421
438 Added 7.86%
6,011 $806,000
Q2 2022

Jul 12, 2022

BUY
$137.62 - $174.96 $177,254 - $225,348
1,288 Added 30.06%
5,573 $853,000
Q1 2022

Apr 18, 2022

BUY
$131.98 - $163.75 $195,858 - $243,005
1,484 Added 52.98%
4,285 $694,000
Q4 2021

Jan 21, 2022

BUY
$107.43 - $135.93 $300,911 - $380,739
2,801 New
2,801 $379,000
Q3 2021

Oct 13, 2021

SELL
$106.4 - $120.78 $263,127 - $298,688
-2,473 Closed
0 $0
Q2 2021

Jul 16, 2021

BUY
$105.21 - $117.21 $260,184 - $289,860
2,473 New
2,473 $278,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Everhart Financial Group, Inc. Portfolio

Follow Everhart Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everhart Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Everhart Financial Group, Inc. with notifications on news.